Every material Form 8-K Pacira BioSciences filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Pacira reported third-quarter 2025 total revenues of $179.5 million, up from $168.6 million a year earlier, and GAAP net income of $5.4 million, or $0.12 per share, compared with a net loss of $143.5 million a year earlier that included a $163.2 million goodwill impairment. The company lowered its full-year 2025 total revenue guidance to $725 million to $735 million from $730 million to $750 million, while raising its non-GAAP gross margin guidance to 80 to 82 percent from 78 to 80 percent.
Q3 2025 total revenues were $179.5 million, versus $168.6 million in Q3 2024; EXPAREL net product sales were $139.9 million, with volume growth of 9 percent.
GAAP net income was $5.4 million, or $0.12 per share, versus a GAAP net loss of $143.5 million, or $3.11 per share, in Q3 2024.
2025 total revenue guidance was cut to $725 million to $735 million from $730 million to $750 million; non-GAAP gross margin guidance was raised to 80 to 82 percent from 78 to 80 percent.
Pacira repurchased 2.0 million shares for $50.0 million in Q3 2025 and had $200.0 million remaining on its authorization at September 30, 2025, which expires December 31, 2026.
Pacira BioSciences reported second-quarter 2025 total revenue of $181.1 million, up from $178.0 million a year earlier, but swung to a GAAP net loss of $4.8 million from net income of $18.9 million. The company narrowed its full-year 2025 revenue guidance to $730 million to $750 million and raised its non-GAAP gross margin guidance to 78 to 80 percent, while non-GAAP net income and adjusted EBITDA both declined year over year.
Total revenue $181.1 million versus $178.0 million in Q2 2024; EXPAREL net product sales $142.9 million.
GAAP net loss of $4.8 million, or $0.11 per share, versus GAAP net income of $18.9 million, or $0.41 per share (basic), in Q2 2024.
Non-GAAP net income $36.0 million, or $0.74 per share (diluted), versus $44.2 million, or $0.89 per share (diluted), a year earlier.
Full-year 2025 revenue guidance narrowed to $730 million to $750 million from $725 million to $765 million; non-GAAP gross margin guidance raised to 78 to 80 percent from 76 to 78 percent.
Pacira BioSciences said on July 9, 2025, it reduced its workforce by 71 employees, about 8% of its total, at its San Diego Science Center Campus after decommissioning its 45-liter EXPAREL manufacturing suite. The company expects pre-tax charges of $2.4 million to $2.8 million in the third quarter of 2025, plus $5.4 million in accelerated depreciation. It estimates the move will cut annual operating expenses by about $13 million.
Reduction in force of 71 employees, about 8% of total workforce, at the San Diego Science Center Campus, instituted July 9, 2025
Company is decommissioning its 45-liter EXPAREL batch manufacturing suite, citing its 200+ liter suites in San Diego and Swindon, UK
Expected pre-tax charges of $2.4 million to $2.8 million in Q3 2025, all cash based, plus $5.4 million in accelerated depreciation
Estimated annual reduction in operating expenses of approximately $13 million, before implementation costs
On July 3, 2025, Pacira BioSciences entered into a new credit agreement with Wells Fargo as administrative agent, providing a $300.0 million senior secured revolving facility maturing July 3, 2030. The company used part of the revolving loans to repay and terminate its existing term loan A credit agreement, with no prepayment penalties or fees reported. The filing is a refinancing and working capital arrangement, with no change to reported earnings or guidance.
Revolving credit facility with aggregate commitment of $300.0 million, maturing July 3, 2030
Secured by substantially all assets of the company and subsidiary guarantors
Existing term loan A credit agreement from March 31, 2023 repaid and terminated, with no prepayment penalties or fees
Interest spreads of 1.50% to 2.25% (base rate) and 2.50% to 3.25% (term SOFR), tied to senior secured net leverage
At its June 10, 2025 annual meeting, Pacira BioSciences stockholders approved an amended and restated 2011 Stock Incentive Plan that increases the shares authorized for grant by 2,500,000, and elected three Class II directors. Stockholders rejected the advisory say-on-pay vote, with 22,595,202 votes against and 14,752,829 for, and the board will hold say-on-pay votes every year.
Stock incentive plan approved: 22,043,902 for, 15,317,588 against, 20,318 abstain, 8,909,022 broker non-votes; 2,500,000 newly reserved shares
Advisory say-on-pay vote failed: 14,752,829 for, 22,595,202 against, 33,777 abstain; board will hold these votes annually
Marcelo Bigal, Frank D. Lee and Alethia Young elected as Class II directors to serve until the 2028 annual meeting; KPMG LLP ratified for fiscal 2025 with 40,022,569 for
Pacira BioSciences reported first quarter 2025 total revenues of $168.9 million, up from $167.1 million a year earlier, while GAAP net income fell to $4.8 million, or $0.10 per share, from $9.0 million, or $0.19 per share. The company reiterated its full-year 2025 revenue guidance of $725 million to $765 million, so shareholders see higher sales alongside lower reported profit.
Total revenues were $168.9 million versus $167.1 million a year earlier, with EXPAREL net product sales of $136.5 million versus $132.4 million.
GAAP net income was $4.8 million, or $0.10 per share, compared with $9.0 million, or $0.19 per share, in the first quarter of 2024.
Adjusted EBITDA was $44.1 million versus $44.6 million, and non-GAAP net income was $30.0 million versus $31.1 million.
Full-year 2025 total revenue guidance of $725 million to $765 million was reiterated, and the company cited a $300 million stock buyback program.
Pacira and its subsidiary settled all outstanding claims in patent litigation over EXPAREL with Fresenius Kabi, eVenus and Jiangsu Hengrui. Under the agreement, Pacira will license Fresenius Kabi to sell volume-limited amounts of generic bupivacaine liposome injectable suspension in the U.S. starting in early 2030, with unlimited generic sales permitted from 2039, both before the July 2, 2044 expiration of the last Orange Book-listed EXPAREL patent. Pacira will also pay the Fresenius Parties $7.0 million, which it said reflects expected savings from avoiding continued litigation costs.
Settlement entered April 7, 2025, covering seven listed patent infringement suits and related actions
Volume-limited generic entry starts in early 2030 at a confidential percentage that begins in the high single digits of U.S. volumes and rises to a maximum in the high thirties
Unlimited generic license begins no earlier than 2039, before the July 2, 2044 patent expiration
Pacira will pay the Fresenius Parties $7.0 million; the full agreement will be filed with the 10-Q for the quarter ending March 31, 2025
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Pacira BioSciences filing is on SEC EDGAR ↗. 8-K briefs of other companies →